New: Introducing the Finviz Crypto Map

Learn More
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#121 / 200 Total
RAY - Raytech Holding Ltd - Stock Price Chart
TickerRAY [NASD]
CompanyRaytech Holding Ltd
CountryHong Kong
IndustryHousehold & Personal Products
Market Cap41.03MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B4.35EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own81.76%Inst Own1.42%
Insider Trans0.00%Inst Trans0.25%
Short Float0.97%Earnings-
Analyst Recom-Target Price-
Avg Volume1.45M52W Range0.86 - 3.80
Raytech Holding Ltd. engages in the sourcing and wholesaling of personal care and lifestyle electrical appliances for international brand owners through its subsidiary. The company was founded by Tim Hoi Ching on June 24, 2022 and is headquartered in Hong Kong.
UPC - Universe Pharmaceuticals INC - Stock Price Chart
TickerUPC [NASD]
CompanyUniverse Pharmaceuticals INC
CountryChina
IndustryDrug Manufacturers - Specialty & Generic
Market Cap1.84MEPS (ttm)61196.14
P/E0.00EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.10EPS next 5Y-
P/B0.03EPS Q/Q99.56%
Dividend-Sales Q/Q-28.96%
Insider Own1.91%Inst Own0.05%
Insider Trans0.00%Inst Trans-98.05%
Short Float6.10%Earnings-
Analyst Recom-Target Price-
Avg Volume286.75K52W Range2.51 - 2423.88
Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.
ALMU - Aeluma Inc - Stock Price Chart
TickerALMU [NASD, RUT]
CompanyAeluma Inc
CountryUSA
IndustrySemiconductors
Market Cap285.74MEPS (ttm)-0.27
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S78.72EPS next 5Y-
P/B15.88EPS Q/Q239.82%
Dividend-Sales Q/Q264.93%
Insider Own48.81%Inst Own5.62%
Insider Trans0.00%Inst Trans-2.06%
Short Float8.53%EarningsMay 28
Analyst Recom1.00Target Price26.00
Avg Volume344.17K52W Range2.50 - 19.80
Aeluma, Inc. engages in the business of developing novel optoelectronic devices for sensing and communications applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.
VREX - Varex Imaging Corp - Stock Price Chart
TickerVREX [NASD, RUT]
CompanyVarex Imaging Corp
CountryUSA
IndustryMedical Devices
Market Cap300.46MEPS (ttm)-1.06
P/E-EPS this Y-27.04%
Forward P/E10.49EPS next Y72.00%
PEG-EPS past 5Y-
P/S0.36EPS next 5Y21.44%
P/B0.55EPS Q/Q296.47%
Dividend-Sales Q/Q3.25%
Insider Own1.31%Inst Own94.07%
Insider Trans-2.74%Inst Trans0.19%
Short Float2.99%EarningsMay 08/a
Analyst Recom1.40Target Price16.60
Avg Volume452.05K52W Range6.76 - 16.93
Varex Imaging Corp. engages in the design, manufacture, and sale of imaging components. It operates through the Medical and Industrial segments. The Medical segment delivers and services x-ray imaging components, including X-ray tubes, digital detectors, high voltage connectors, image-processing software and workstations, and three-dimensional reconstruction software. The Industrial segment offers x-ray imaging products for use in security, and nondestructive testing and inspection applications. The company was founded in 2016 and is headquartered in Salt Lake City, UT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kunkel Jay K.DirectorJun 18 '25Sale7.772,57520,00822,477Jun 20 05:16 PM
Kunkel Jay K.DirectorJun 18 '25Proposed Sale7.772,57520,008Jun 18 10:55 AM
SANYAL SUNNYPresident and CEOApr 02 '25Sale11.248,74998,339190,193Apr 03 05:35 PM
SANYAL SUNNYOfficerApr 02 '25Proposed Sale11.248,74998,339Apr 02 10:56 AM
Honeysett Kimberley E.SVP and CLOMar 20 '25Sale12.814,00751,3304,002Mar 21 04:34 PM
ARTV - Artiva Biotherapeutics Inc - Stock Price Chart
TickerARTV [NASD]
CompanyArtiva Biotherapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap58.23MEPS (ttm)-2.98
P/E-EPS this Y43.44%
Forward P/E-EPS next Y2.60%
PEG-EPS past 5Y-64.01%
P/S-EPS next 5Y23.59%
P/B0.34EPS Q/Q-5.07%
Dividend-Sales Q/Q-100.00%
Insider Own49.52%Inst Own63.60%
Insider Trans0.00%Inst Trans-3.13%
Short Float5.28%EarningsMay 08/b
Analyst Recom1.00Target Price15.40
Avg Volume233.61K52W Range1.47 - 17.31
May-28-25 04:05PM Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) +6.77%
May-13-25 04:05PM Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting (GlobeNewswire) -11.71%
May-08-25 08:00AM Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights (GlobeNewswire)
Apr-28-25 04:35PM Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting (GlobeNewswire)
Apr-08-25 04:05PM Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer (GlobeNewswire) -41.99%
Mar-31-25 04:05PM Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.06%
Mar-24-25 04:05PM Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -8.43%
Feb-20-25 04:05PM Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -5.72%
Jan-29-25 04:05PM Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. (GlobeNewswire)
Nov-12-24 04:05PM Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -10.48%
Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorJul 22 '24Buy12.008,333,33399,999,9968,693,579Jul 24 04:27 PM
5AM Partners VI, LLC10% OwnerJul 22 '24Buy12.00833,3339,999,9961,182,054Jul 24 04:15 PM
venBio Global Strategic Fund I10% OwnerJul 22 '24Buy12.00416,6664,999,9921,936,637Jul 22 08:26 PM
GC Corp.10% OwnerJul 22 '24Buy12.001,666,66619,999,9923,306,900Jul 22 08:25 PM
GC Corp.10% OwnerJul 22 '24Buy12.00416,6664,999,9921,260,512Jul 22 08:25 PM
RCAT - Red Cat Holdings Inc - Stock Price Chart
TickerRCAT [NASD, RUT]
CompanyRed Cat Holdings Inc
CountryUSA
IndustryComputer Hardware
Market Cap1.11BEPS (ttm)-0.54
P/E-EPS this Y29.34%
Forward P/E130.03EPS next Y121.67%
PEG-EPS past 5Y-47.70%
P/S67.35EPS next 5Y-
P/B33.39EPS Q/Q-174.24%
Dividend-Sales Q/Q-72.13%
Insider Own20.32%Inst Own19.37%
Insider Trans-1.72%Inst Trans-38.95%
Short Float20.23%EarningsMay 14/a
Analyst Recom1.00Target Price13.33
Avg Volume8.50M52W Range1.64 - 15.27
Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Liuzza Nicholas Reyland JRDirectorJun 10 '25Sale8.58100,000858,000387,445Jul 09 05:09 PM
Liuzza Nicholas Reyland JRDirectorMay 21 '25Sale6.70100,309671,769387,445Jul 09 05:09 PM
Freedman Joseph DavidDirectorJun 30 '25Option Exercise2.51150,000376,500315,260Jul 07 06:24 PM
Freedman Joseph DavidDirectorJun 30 '25Sale7.37150,0001,105,500165,260Jul 07 06:24 PM
Lunger LeahChief Financial OfficerJan 03 '25Option Exercise1.277,0838,995329,541Jan 07 06:15 PM
QLGN - Qualigen Therapeutics Inc - Stock Price Chart
TickerQLGN [NASD]
CompanyQualigen Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap4.92MEPS (ttm)-33.17
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y79.32%
P/S-EPS next 5Y-
P/B-EPS Q/Q95.01%
Dividend-Sales Q/Q-
Insider Own6.96%Inst Own0.53%
Insider Trans0.00%Inst Trans-11.07%
Short Float1.79%Earnings-
Analyst Recom1.00Target Price250.00
Avg Volume826.99K52W Range2.85 - 16.17
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.
LYRA - Lyra Therapeutics Inc - Stock Price Chart
TickerLYRA [NASD]
CompanyLyra Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap12.63MEPS (ttm)-60.71
P/E-EPS this Y88.33%
Forward P/E-EPS next Y7.81%
PEG-EPS past 5Y-2.22%
P/S10.61EPS next 5Y42.99%
P/B2.69EPS Q/Q62.94%
Dividend-Sales Q/Q-65.60%
Insider Own0.00%Inst Own30.35%
Insider Trans-Inst Trans-8.72%
Short Float7.74%EarningsMay 06/a
Analyst Recom3.00Target Price23.00
Avg Volume709.14K52W Range3.81 - 37.50
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Palasis MariaPresident & CEOJul 10 '25Sale8.911,56513,9441,098,435Jul 14 09:27 PM
Cavalier JasonChief Financial OfficerJul 10 '25Sale8.916846,094519,316Jul 14 09:27 PM
Palasis MariaOfficerJul 10 '25Proposed Sale8.911,56513,945Jul 10 04:05 PM
Waksal HarlanOfficerApr 25 '25Proposed Sale0.10145,37014,930Apr 25 03:41 PM
Palasis MariaOfficerApr 09 '25Proposed Sale0.0939,5673,545Apr 09 03:44 PM
AREN - Arena Group Holdings Inc - Stock Price Chart
TickerAREN [AMEX, RUT]
CompanyArena Group Holdings Inc
CountryUSA
IndustryInternet Content & Information
Market Cap249.22MEPS (ttm)0.06
P/E93.57EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y34.07%
P/S1.94EPS next 5Y-
P/B-EPS Q/Q102.17%
Dividend-Sales Q/Q9.93%
Insider Own81.47%Inst Own4.73%
Insider Trans0.00%Inst Trans3.92%
Short Float7.62%EarningsMay 15/a
Analyst Recom1.00Target Price11.00
Avg Volume305.87K52W Range0.56 - 10.05
The Arena Group Holdings, Inc. is a data-driven media company that focuses on building deep content verticals powered by a digital media platform (the Platform), empowering premium publishers who impact, inform, educate, and entertain. It focuses on leveraging the Platform and iconic brands in targeted verticals to maximize the audience, improve engagement, and optimize monetization of digital publishing assets for the benefit of its users, advertiser clients, and its owned and operated properties as well as properties the firm runs on behalf of its independent publisher partners. The company operates the media businesses for Sports Illustrated, TheStreet, Inc., and College Spun Media Incorporated. It also powers independent publisher partners, including Biography, History, and FanNation. The company was founded by James C. Heckman Jr. on October 1, 1990 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lee Laura AnneDirectorFeb 12 '25Sale1.4055,78078,0920Feb 13 04:00 PM
Randall CavittDirectorFeb 12 '25Buy1.4055,78078,092290,958Feb 13 04:00 PM
Petzel ChristopherDirectorFeb 03 '25Sale1.3525,01033,7640Feb 04 04:00 PM
Randall CavittDirectorFeb 03 '25Buy1.3525,01033,764235,178Feb 04 04:00 PM
Petzel ChristopherDirectorJan 17 '25Sale1.2325,00030,75025,010Jan 22 04:00 PM
CNTB - Connect Biopharma Holdings Ltd ADR - Stock Price Chart
TickerCNTB [NASD]
CompanyConnect Biopharma Holdings Ltd ADR
CountryUSA
IndustryBiotechnology
Market Cap95.20MEPS (ttm)-0.28
P/E-EPS this Y-208.54%
Forward P/E-EPS next Y22.77%
PEG-EPS past 5Y7.77%
P/S3.66EPS next 5Y-24.19%
P/B1.15EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own5.11%
Insider Trans-Inst Trans-0.05%
Short Float0.05%EarningsMay 15/b
Analyst Recom1.00Target Price6.55
Avg Volume113.02K52W Range0.51 - 1.86
Today 09:00AM Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire) -7.53%
Jul-17-25 09:00AM Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +14.81%
Jul-09-25 09:00AM Connect Biopharma's Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China (GlobeNewswire)
Jun-13-25 09:00AM Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress (GlobeNewswire) +11.76%
Jun-03-25 09:00AM Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress (GlobeNewswire)
May-28-25 09:00AM Connect Biopharma to Present at Two Upcoming Investor Conferences in June (GlobeNewswire)
May-20-25 09:00AM Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire) +8.12%
May-15-25 09:00AM Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.58%
May-14-25 09:00AM Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD (GlobeNewswire)
05:25AM Connect Biopharma begins Phase II trial of drug for acute exacerbations in asthma (Clinical Trials Arena)
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. It focuses on advancing rademikibart, an anti-interleukin-4-receptor alpha antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wei Zheng10% OwnerJun 11 '25Proposed Sale0.8139,77532,218Jun 11 08:02 AM
18910111213141516171820